- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04397705
Remote Monitoring of Cancer Patients With Suspected Covid-19 (RECAP)
Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.
Since emerging in December 2019, coronavirus disease 2019 (Covid-19) has developed into an unprecedented global pandemic. The causative pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to cause a wide range of clinical syndromes, from fever, dyspnoea and cough to respiratory failure and cardiac injury necessitating critical care support. A number of patients have a more indolent clinical course and can be safely managed in the community.
Characterising the clinical course of Covid-19 infection in the oncology population and distinguishing this from other acute oncology presentations which can mimic Covid-19 is a key unmet research need. Current standard of care for monitoring patients at high risk of chemotherapy associated neutropenic sepsis involves asking them to contact their cancer centre when they feel unwell or develop a fever. No standard of care for monitoring ambulatory Covid-19 patients has yet been established. We hypothesise that using wearable biosensors to detect patients who exhibit 'red flags' for sepsis or deterioration due to Covid-19 may allow earlier assessment and intervention. There is no current evidence for wearable biosensors in ambulatory patients receiving chemotherapy, and there is no existing research into this proposed use of biosensors in patients with suspected or confirmed Covid-19 infection.
In order to justify performing a randomised controlled study comparing standard of care with biosensor driven monitoring it is important to establish the tolerability and validity of these devices. We aim to collect patient reported outcome measures (PROMs) on tolerability and assess the reliability of data transmission to a central data collection server. We will also perform an initial analysis of physiological data and correlation with clinical events
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is a pilot, single arm, open label feasibility study. This is a single centre trial based in a large tertiary cancer centre which treats patients across all solid and haematological malignancies. Patients will be recruited from all disease groups.
Patients who present with symptoms suspicious for Covid-19 who the admitting clinicians deems appropriate for outpatient management will be considered for this study.
Patients who are enrolled will undergo continuous physiological monitoring for up to three weeks. This includes continuous monitoring of heart rate, respiratory rate, temperature, activity levels (by accelerometer measurement) and twice daily pulse oximetry. The physiological data will not be reviewed in real time by clinicians and therefore will not be used to alter patients' standard care. The pulse oximetry data will be visible to patients who will be given clear guidelines to follow with regards to contacting the cancer centre hotline should values deviate from baseline.
In the pilot phase of RECAP 10-30 patients will each be monitored for up to 3 weeks and the following endpoints will be addressed:
Physiological trends and interactions predictive of clinical deterioration due to COVID-19 (Co-primary endpoint) Reliability of biosensor data collection/transmission using digital technology from patients self-isolating at home (Co-primary endpoint) Acceptability and tolerability of wearable biosensors and continuous monitoring If the pilot phase is successful we will move to a phase II study in a larger number of patients where the objective will be to refine a physiological signature predictive of clinical deterioration in COVID-19 patients so that early hospitalisation and relevant medical interventions can be arranged.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Wes Dale
- Numer telefonu: 7902 01614463000
- E-mail: wes.dale@christie.nhs.uk
Lokalizacje studiów
-
-
Greater Manchester
-
Manchester, Greater Manchester, Zjednoczone Królestwo, M204BX
- Rekrutacyjny
- The Christie NHS Foundation Trust
-
Kontakt:
- Wes Dale
- Numer telefonu: +44 1619187902
- E-mail: Wes.dale@christie.nhs.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Participants are capable of giving informed consent
- Male or female aged 18 or over
Diagnosis of any solid tumour or haematological malignancy meeting one of the following criteria:
- Current malignant diagnosis
- Received anti-cancer treatment within the last two years
- Emergency presentation to hospital with symptoms consistent with Covid-19 deemed to meet the criteria for Covid-19 testing by admitting clinician.
- Deemed by the admitting clinician to be suitable for outpatient management of suspected Covid-19.
- Stable oxygen saturations of 95% or higher at time of emergency presentation.
- Able to complete tolerability questionnaire.
- Able and willing to comply with twice daily pulse oximetry monitoring as outlined in section 6 of the protocol.
- ECOG-PS <4
- Life expectancy of greater than three months as assessed by screening investigator from review of electronic patient record.
Exclusion Criteria:
- Patients hospitalized for more than 24 hours at initial presentation with symptoms consistent with Covid-19.
- Pregnant patients.
- Patients unable to give informed consent.
- Presence of ulceration or pre-existing skin rash at site of device application (left precordium and axillae). If only one axilla affected this is not an exclusion criterion if patient is happy to apply temperature sensor to the other axilla.
- Radiotherapy to the left chest wall either during or within the six months preceding the study. Plans for subsequent radiotherapy to commence after study completion are not an exclusion criterion. If only one axilla is within the planned radiotherapy field and patient is happy to apply temperature sensor to the other axilla this is not an exclusion criteria.
- History of allergy or contact dermatitis to medical adhesives e.g sticking plasters, ECG electrodes.
- Patients with pacemakers, implantable defibrillators or neurostimulators.
- Patients who are currently receiving treatment as part of a clinical study or have had their end of treatment visit for another clinical study less than 30 days prior to the study enrollment visit.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Ambulatory monitoring
Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks.
Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
|
Wearable sensors
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Device Tolerability (Attrition)
Ramy czasowe: Three weeks
|
Percentage of patients who choose to stop wearing the devices before they have completed the study
|
Three weeks
|
Correlation of physiological data with clinical events
Ramy czasowe: Over three weeks of patients wearing devices
|
Correlation of sensor collected data with clinical episodes of infection.
Sensor collected data includes heart rate, respiratory rate and temperature.
|
Over three weeks of patients wearing devices
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Device Tolerability (Questionnaire)
Ramy czasowe: Questionnaire at three weeks
|
Percentage of participants who answer 'agree' or 'strongly agree' on a five point Likert scale to the statement 'I would be happy to wear the sensors again for the next three weeks'.
This statement is included in the questionnaires completed after three weeks of wearing the device.
|
Questionnaire at three weeks
|
Device Tolerability (Semi-structured interviews)
Ramy czasowe: One to four weeks after completion of wearing the device
|
Device tolerability as assessed by semi-structured interviews.
|
One to four weeks after completion of wearing the device
|
Reliability of data transmission
Ramy czasowe: Over three weeks of patients wearing devices
|
Reliable data transmission to central hospital system expressed as a percentage of total data points collected out of target data points collected.
|
Over three weeks of patients wearing devices
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: John Radford, The University of Manchester
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CFTSp186
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na COVID
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustZakończonyCOVIDZjednoczone Królestwo
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... i inni współpracownicyZakończony
-
Indonesia UniversityRekrutacyjnySyndrom po COVID-19 | Długi COVID | Stan po COVID-19 | Syndrom post-COVID | Długi COVID-19Indonezja
-
Sultan Qaboos UniversityZakończonyCOVID-19 | Nie-CovidOman
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ZakończonyOstre następstwa COVID-19 | Stan po COVID-19 | Długi-COVID | Przewlekły zespół Covid-19Włochy
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkJeszcze nie rekrutacjaSyndrom po COVID-19 | Długi COVID | Długi Covid19 | Stan po COVID-19 | Syndrom post-COVID | Stan po COVID-19, nieokreślony | Stan po Covid-19Holandia
-
StemCyte, Inc.RekrutacyjnyDługi COVID | Stan po COVID-19 | Syndrom post-COVIDStany Zjednoczone
-
Miami VA Healthcare SystemJeszcze nie rekrutacjaDługi COVIDStany Zjednoczone
-
Medical University of ViennaRekrutacyjnyChoroby nerwu błędnego | Syndrom po COVID-19 | Długi COVID | Długi Covid19 | Stan po COVID-19 | Syndrom post-COVID | Stan po COVIDAustria
-
Lawson Health Research InstituteWestern UniversityJeszcze nie rekrutacjaZmęczenie | Syndrom po COVID-19 | Długi Covid19 | Syndrom post-COVID | Długi-COVID
Badania kliniczne na Patient Status Engine
-
The Christie NHS Foundation TrustManchester University NHS Foundation Trust; Aptus Clinical Ltd.; Zenzium Ltd.Zakończony
-
University of Illinois at ChicagoRekrutacyjnyRak szyjki macicy | ZachowanieSenegal
-
University of Colorado, DenverUniversity of Alabama at Birmingham; Brown UniversityZakończony
-
University of Colorado, DenverNational Institute of Nursing Research (NINR); Kaiser Permanente; Denver Health...ZakończonyOpieka paliatywnaStany Zjednoczone
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationRekrutacyjnyMukowiscydoza | Status rodzicielskiStany Zjednoczone
-
Duke UniversityZakończonyNadciśnienie | Choroba nerekStany Zjednoczone
-
Universidad de MurciaZakończony
-
Alsayed Mohamed Alsayed AlsadanyNieznany
-
Fachklinik Hornheide an der Universität MünsterWestfälische Wilhelms-Universität Münster; Deutsche RentenversicherungZakończonyJakość życia | Zdolność do pracy | Czerniak złośliwy skóryNiemcy
-
University of DerbyNieznanyWirus brodawczaka ludzkiego, migdałek podniebiennyZjednoczone Królestwo